Concord Biotech, the Ahmedabad-based fermentation-based active pharmaceutical ingredient (API) maker backed by Rare Enterprises and Quadria Capital, filed its Draft Red Herring Prospectus (DRHP) with market regulator Securities and Exchange Board of India (SEBI) for an initial public offering (IPO).

Sources told ET that the IPO would be of ₹2000 crore – ₹2500 crore size.

The issue with a face value of ₹1 per equity share is a complete offer for sale (OFS) aggregating to 20,925,652 equity shares by Helix Investment Holdings Pte. Limited. The offer also includes a reservation for a subscription by eligible employees.

The offer is being made through the book-building process, wherein not more than 50% of the offer shall be available for allocation to qualified institutional buyers, up to 15% will be available for allocation to non-institutional bidders and the remainder for retail investors.

As per DRHP, Concord has a market share of over 20% by volume in 2021 across identified fermentation-based API products including dactinomycin, sirolimus, tacrolimus, and mycophenolate sodium, and cyclosporine. It supplies to over 70 countries including regulated markets such as the US, Europe, Japan, and India.

The company’s revenue from operations increased by 15.6% year-on-year (YoY) to Rs 712.93 crore for FY22.

“What lies behind us and what lies before us are small matters compared to what lies within us.” – Oliver Wendell Holmes


Source link

By Dipak

Leave a Reply

Your email address will not be published.